Interview with Jan Slob, President, Akrikhin
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
Address: 52, bld 5, Kosmodamianskaya Naberezhnaya,Moscow, Russia, 115054,Russia
Tel: + 7 (495) 721 36 97
AKRIKHIN founded in 1936, is one of the leading Russian pharmaceutical producer of high-quality medicines on the Russian pharmaceutical market. By 2010 results AKRIKHIN is the 5th largest local producer by revenue and production volume on the Russian pharmaceutical market.
AKRIKHIN product portfolio counts more than 150 products focused within strategically selected Anatomo Therapeutic Classes including cardiovascular, neurology, dermatology, gynecology, pediatrics. AKRIKHIN produces a wide range of socially important medications thus making a tangible input into the development of the Russian healthcare system. AKRIKHIN is a major Russian producer of Essential Drugs which account up to 70% share of the Company product portfolio. Special emphasis is made on strategic directions of high social value – production of drugs for diabetes and tuberculosis treatment.
With the Company Field Force operating in 76 cities all across Russia and highly professional marketing team AKRIKHIN has succeeded in forming a wide and well-diversified product portfolio well recognized by doctors.
AKRIKHIN production facilities is a consolidated GMP-oriented complex located 30 km from Moscow with the workshops for production of a vast spectre of drug forms: tablets, capsules, ointments, gels, creams, syrups, etc. AKRIKHIN production existing capacities amount to more than 50 mln packs per year.
Starting from 2007 AKRIKHIN entered a strategic alliance with Polpharma – the largest Polish manufacturer of generic drugs and pharmaceutical substances. AKRIKHIN and Polpharma strategic partnership embracesincorporates common product portfolio, production technologies transfer, R&D cooperation, access to best European practices and standards, joint educational programmes for personnel.
In the “Rating of influence of Russian pharmaceutical market participants” based on pharmaceutical market experts’ opinions “AKRIKHIN” is included into the TOP 3 most authoritative and influential Russian pharmaceutical producers upon the results of 2010.
AKRIKHIN priding on its 75-years’ history and traditions builds on its successful performance on the Russian pharmaceutical market, dynamically adapting itself to modern business practices and technologies.
In its portfolio of more than 150 products of various dosage forms: tablets, capsules, creams, suppositories, creams, syrups. Akrihin focuses on therapeutic areas with high social importance, ie most sought-after Russian health care system: cardiology, diabetes, neurology, dermatology, tuberculosis, gynecology and pediatrics
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here